Skip to main content

Table 1 Baseline characteristics of the study groups

From: Metformin induces a prompt decrease in LH-stimulated testosterone response in women with PCOS independent of its insulin-sensitizing effects

  Metformin Placebo
No. of subjects 10 9
Age (yrs) 26.10 ± 4.25 27.89 ± 4.83
Weight (kg) 78.97 ± 21,86 95.26 ± 21.64
BMI (kg/m2) 29.90 ± 7.41 32.15 ± 6.10
No. with oligomenorrhea (%) 10 (100%) 8 (89%)
No. with PCO on ultrasound (%) 8 (80%) 7 (78%)
Total testosterone (μg/l) 0.58 ± 0.24 0.66 ± 0.36
SHBG (nmol/l) 35.60 ± 24.09 39.02 ± 33.30
Free testosterone (pg/ml) 1.77 ± 0.99 1.92 ± 0.91
Androstendione (μg/l) 3.65 ± 1.47 3.61 ± 0.91
17-OHP (μg/l) 1.35 ± 0.37 1.22 ± 0.49
Free androgen Index 7.78 ± 4.96 7.92 ± 3.26
Estradiol (ng/l) 36.56 ± 14.06 48.00 ± 20.77
DHEAS (mg/l) 2.50 ± 0.97 1.84 ± 0.79
Fasting glucose (mg/dl) 81.80 ± 6.03 86.89 ± 6.57
AUC glucose 18409.70 ± 2059.30 17987.67 ± 2264.72
(mg/dl x 180 min)
Fasting insulin (μIU/ml) 11.06 ± 6.38 18.04 ± 10.66
AUC insulin 12754.40 ± 8060.54 16671 ± 12663.37
(μUI/ml x 180 min)
No. with IR* (%) 3 (30%) 5 (56%)
  1. Data are given as mean ± SEM unless otherwise noted.
  2. *IR was defined as AUC insulin > 12,000 μUI/ml x 180 min.